{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:49:34Z","timestamp":1793238574914,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019271","name":"Kyorin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002951","name":"Dokkyo Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002951","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ejphar.2022.175272","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T03:40:18Z","timestamp":1663040418000},"page":"175272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Inhibitory effects of vibegron, a \u03b23-adrenoceptor agonist, on the myogenic contractile and mechanosensitive afferent activities in an obstructed rat bladder"],"prefix":"10.1016","volume":"933","author":[{"given":"Naoki","family":"Aizawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoe","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175272_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173995","article-title":"Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and beta3-adrenoceptor agonist or anticholinergic agent on bladder dysfunction in rats with bladder overactivity","volume":"899","author":"Aizawa","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175272_bib2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.eururo.2012.08.056","article-title":"Effects of mirabegron, a novel beta3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin","volume":"62","author":"Aizawa","year":"2012","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2022.175272_bib3","doi-asserted-by":"crossref","first-page":"7646","DOI":"10.1038\/s41598-017-07898-y","article-title":"Characteristics of the mechanosensitive bladder afferent activities in relation with microcontractions in male rats with bladder outlet obstruction","volume":"7","author":"Aizawa","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2022.175272_bib4","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/nau.23547","article-title":"Inhibitory effects of silodosin on the bladder mechanosensitive afferent activities and their relation with bladder myogenic contractions in male rats with bladder outlet obstruction","volume":"37","author":"Aizawa","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.ejphar.2022.175272_bib5","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1464-410X.2006.06564.x","article-title":"The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder","volume":"98","author":"Biers","year":"2006","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2022.175272_bib6","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00210-012-0767-6","article-title":"Specificity evaluation of antibodies against human beta3-adrenoceptors","volume":"385","author":"Cernecka","year":"2012","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175272_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pain.2006.09.023","article-title":"Convergence of bladder and colon sensory innervation occurs at the primary afferent level","volume":"128","author":"Christianson","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2022.175272_bib8","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/nau.23224","article-title":"Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: an immunohistochemical study","volume":"36","author":"Coelho","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.ejphar.2022.175272_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2015.03.074","article-title":"Involvement of beta3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor","volume":"758","author":"D' Agostino","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175272_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.urology.2004.08.063","article-title":"The urothelium in overactive bladder: passive bystander or active participant?","volume":"64","author":"de Groat","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2022.175272_bib11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.116.237313","article-title":"Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder","volume":"360","author":"Di Salvo","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2022.175272_bib12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00210-015-1122-5","article-title":"The expression of beta3-adrenoceptor and muscarinic type 3 receptor immuno-reactivity in the major pelvic ganglion of the rat","volume":"388","author":"Eastham","year":"2015","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175272_bib13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","article-title":"Discovery of vibegron: a potent and selective beta3 adrenergic receptor agonist for the treatment of overactive bladder","volume":"59","author":"Edmondson","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2022.175272_bib14","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00210-020-01921-2","article-title":"Additive effects of intravenous and intravesical application of vibegron, a beta3-adrenoceptor agonist, on bladder function in rats with bladder overactivity","volume":"393","author":"Furuta","year":"2020","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175272_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1006903507321","article-title":"Distribution of afferent axons in the bladder of rats","volume":"27","author":"Gabella","year":"1998","journal-title":"J. Neurocytol."},{"key":"10.1016\/j.ejphar.2022.175272_bib16","doi-asserted-by":"crossref","first-page":"E132","DOI":"10.1111\/j.1464-410X.2012.11240.x","article-title":"Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the beta(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction","volume":"110","author":"Gillespie","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2022.175272_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00210-012-0814-3","article-title":"Effect of mirabegron, a novel beta3-adrenoceptor agonist, on bladder function during storage phase in rats","volume":"386","author":"Hatanaka","year":"2013","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175272_bib18","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/bph.14658","article-title":"beta3 -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions?","volume":"176","author":"Igawa","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175272_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0022-5347(17)34925-X","article-title":"Micturition and premicturition contractions in unanesthetized rats with bladder outlet obstruction","volume":"151","author":"Igawa","year":"1994","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175272_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00210-012-0824-1","article-title":"Pharmacological profile of beta3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome","volume":"386","author":"Igawa","year":"2013","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175272_bib21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/cne.903190411","article-title":"Segmental distribution and peptide content of primary afferent neurons innervating the urogenital organs and colon of male rats","volume":"319","author":"Keast","year":"1992","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.ejphar.2022.175272_bib22","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","article-title":"Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women","volume":"34","author":"Krauwinkel","year":"2012","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejphar.2022.175272_bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/nau.20965","article-title":"Urothelial beta-3 adrenergic receptors in the rat bladder","volume":"30","author":"Kullmann","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.ejphar.2022.175272_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1146\/annurev.ne.11.030188.000305","article-title":"Tachykinins","volume":"11","author":"Maggio","year":"1988","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2022.175272_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173096","article-title":"Effects of vibegron, a novel beta3-adrenoceptor agonist, and its combination with imidafenacin or silodosin in a rat with partial bladder outlet obstruction","volume":"878","author":"Maruyama","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175272_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pharmthera.2016.01.007","article-title":"beta3-Adrenoceptor agonists for overactive bladder syndrome: role of translational pharmacology in a repositioning clinical drug development project","volume":"159","author":"Michel","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2022.175272_bib27","doi-asserted-by":"crossref","first-page":"F859","DOI":"10.1152\/ajprenal.00215.2017","article-title":"Do beta3-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?","volume":"313","author":"Okeke","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2022.175272_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/luts.12007","article-title":"Expression of beta-adrenoceptor subtypes in urothelium, interstitial cells and detrusor of the human urinary bladder","volume":"5","author":"Otsuka","year":"2013","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"10.1016\/j.ejphar.2022.175272_bib29","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMra032662","article-title":"Management of overactive bladder","volume":"350","author":"Ouslander","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175272_bib30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.expneurol.2006.12.024","article-title":"Up-regulation of calcitonin gene-related peptide and receptor tyrosine kinase TrkB in rat bladder afferent neurons following TNBS colitis","volume":"204","author":"Qiao","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2022.175272_bib31","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00210-018-1510-8","article-title":"Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium","volume":"391","author":"Sellers","year":"2018","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175272_bib32","doi-asserted-by":"crossref","first-page":"F388","DOI":"10.1152\/ajprenal.00392.2016","article-title":"Inhibition of cholinergic neurotransmission by beta3-adrenoceptors depends on adenosine release and A1-receptor activation in human and rat urinary bladders","volume":"313","author":"Silva","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejphar.2022.175272_bib33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/luts.12109","article-title":"Synergic suppressive effect of silodosin and imidafenacin on non-voiding bladder contractions in male rats with subacute bladder outlet obstruction","volume":"9","author":"Sugiyama","year":"2017","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"10.1016\/j.ejphar.2022.175272_bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0006-8993(00)02732-3","article-title":"Anatomical evidence for two spinal 'afferent-interneuron-efferent' reflex pathways involved in micturition in the rat: a 'pelvic nerve' reflex pathway and a 'sacrolumbar intersegmental' reflex pathway","volume":"883","author":"Vera","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2022.175272_bib35","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0022-5347(05)65936-8","article-title":"Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat","volume":"166","author":"Woods","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175272_bib36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ar.21327","article-title":"Correlation between the distribution of SP and CGRP immunopositive neurons in dorsal root ganglia and the afferent sensation of preputial frenulum","volume":"294","author":"Wu","year":"2011","journal-title":"Anatomical record (Hoboken, N.J."},{"key":"10.1016\/j.ejphar.2022.175272_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172727","article-title":"Effects of the combination of vibegron and imidafenacin on bladder function in urethane-anesthetized rats","volume":"864","author":"Yamazaki","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175272_bib38","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/iju.13596","article-title":"Long-term safety and efficacy of the novel beta3 -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study","volume":"25","author":"Yoshida","year":"2018","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ejphar.2022.175272_bib39","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","article-title":"Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Yoshida","year":"2018","journal-title":"Eur. Urol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922005337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922005337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:07:34Z","timestamp":1757977654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922005337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":39,"alternative-id":["S0014299922005337"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175272","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory effects of vibegron, a \u03b23-adrenoceptor agonist, on the myogenic contractile and mechanosensitive afferent activities in an obstructed rat bladder","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175272"}}